TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01892982

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving Education tailored to NICU
Study: NCT01618175

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home oxygen therapy
Description: Oxygen will be provided using a generator, through nasal prongs at a flow rate up to 1 L/min.~During home stay the parents will be guided on how to suspect signs of clinical deterioration. General treatment: If oxygen saturation by pulse oximeter is greater than 92%, the oxygen will be reduced by a quarter liter per minute while monitoring for 15 minutes. If oxygen saturation decreased to less than 92% of the child will remain with the best previous oxygen flow until the next visit. Once the child reaches - 0.06 l / min for 15 minutes, he will will be checked back on room air. Cessation of oxygen therapy: when the oxygen saturation remains above 92% on room air. Every day that no home visit was performed a phone call will be done and follow-up questionnaire will be filled daily, including oxygen saturation registration.
Study: NCT01577706

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprazolam
Description: Alprazolam, gel-capsule, 1mg, single-dose, 1-day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextroamphetamine
Description: Dextroamphetamine, gel-capsule, 20mg, single-dose, 1-day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, gel-capsule, single-dose, 1-day
Study: NCT04418882

Intervention type: OTHER
Intervention: management and follow up of all open fractures
Description: to evaluate the development of sepsis after an open fracture and then, if there is a development of a pseudarthrosis too.

Intervention type: OTHER
Intervention: management and follow up of all open fractures
Description: to evaluate the development of sepsis after an open fracture and then, if there is a development of a pseudarthrosis too.
Study: NCT03335553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986235
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986235
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT00566228

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Patients undergo autologous stem cell transplantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: autologous hematopoietic stem cell transplantation
Description: Patients undergo autologous stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: leukapheresis
Description: Stem cells collected

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: leukapheresis
Description: Stem cells collected
Study: NCT01627249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.0 mg intravitreal aflibercept
Description: Intravitreal injection of 2.0 mg aflibercept at baseline and up to every 4 weeks using defined retreatment criteria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.25 mg intravitreal bevacizumab
Description: Intravitreal injection of 1.25 mg bevacizumab at baseline and up to every 4 weeks using defined retreatment criteria.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.3 mg intravitreal ranibizumab
Description: Intravitreal injection of 0.3 mg ranibizumab (Lucentis™) at baseline and up to every 4 weeks using defined retreatment criteria.
Study: NCT03109600

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vi-DT (Bio Farma)
Description: Typhoid Conjugate Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vi-DT (Bio Farma)
Description: Typhoid Conjugate Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vi polysaccharide vaccine
Description: Vi polysaccharide vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vi polysaccharide vaccine
Description: Vi polysaccharide vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenzae vaccine
Description: 1 dose of Influenzae vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal conjugate vaccine
Description: 1 dose of Pneumococcal conjugate Vaccine
Study: NCT02518659

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Inulin
Description: This is the Intervention
Study: NCT04497090

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fixed-EPAP
Description: In the fixed-EPAP mode, the device kept EPAP fixed at the prescribed value

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: auto-EPAP
Description: In the Auto-EPAP mode, the device automatically adjusted EPAP to the minimum level able to abolish tidal expiratory flow limitation.
Study: NCT02579785

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mhealth intervention
Description: A series of ten automated interactive voice messages will be delivered to the participant's mobile phone over a period of 4 months. Messages will be targeted to the method of contraception the participant is using (no-method, condoms, pills, injectable, implant, copper coil). Messages will support uptake of contraception among no-method users. Messages will support existing users to continue their method and to use it correctly and will also encourage participants who are not happy with their method to switch to a different method. All messages will end with five options: Press 1 to repeat the message, press 2 to listen to recorded information about methods of contraception, press 3 to speak to a counsellor, press 4 to tell me you're fine, press 5 to stop receiving these messages.
Study: NCT02077751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biotin labelled RBCs
Description: Autologous red blood cells are biotin labelled and transfused to the subject. Survival of these red blood cells is tracked through examination of blood samples until no biotin labelled red blood cells remain.
Study: NCT02530879

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole, Lansoprazole, Esomeprazole, Rantidine
Description: 1.Omeprazole- Dose range oral, 20mg once a day, up to 40mg twice a day 2.Lansoprazole-Dose range 15mg per day- 30mg twice a day 3.Esomeprazole- Dose range oral, 20mg once a day, up to 40mg twice a day 4.Rantidine-Dose range: 150 mg twice a day or 300 mg

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voice therapy
Description: Evaluation is completed over two, one-hour sessions. Once the evaluation is complete, the subject will begin weekly, individual voice therapy for 55 minute sessions per week with a second year graduate student under the direct supervision of the clinical faculty member.Treatment sessions will include a counseling component and an active exercise program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination of anti-reflux medication and voice therapy
Description: Subjects will receive both anti-reflux medication as detailed above and voice therapy as detailed above.
Study: NCT02693600

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ligamentoplasty with partial trapeziectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ligamentoplasty with total trapeziectomy
Study: NCT00964223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin and benzoyl peroxide gel (Duac® Topical Gel)
Description: Subjects will apply Duac(clindamycin and benzoyl peroxide) gel to one-half of their face and and apply Epiduo (benzoyl peroxide/adapalene) gel on the other side of their face once a day for the first 2 weeks. Starting at week 2, subjects will apply Duac (benzoyl peroxide/clindamycin gel) to the entire face for an additional 6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: benzoyl peroxide and adapalene gel (EPIDUO™ Gel)
Description: Subjects will apply Duac(clindamycin and benzoyl peroxide) gel to one-half of their face and and apply Epiduo (benzoyl peroxide/adapalene) gel on the other side of their face once a day for the first 2 weeks. Starting at week 2, subjects will apply Duac (benzoyl peroxide/clindamycin gel) to the entire face for an additional 6 weeks.
Study: NCT03110393

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu AuraGain
Description: Insert and intubation of an Ambu® AuraGain™ laryngeal mask

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intersurgical i-gel
Description: Insert and intubation of an Intersurgical i-gel®
Study: NCT01340950

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zidovudine-lamivudine-nevirapine
Description: 96 weeks of zidovudine 300 mg orally twice daily, lamivudine 300 mg orally daily, nevirapine 200 mg orally daily for the first 14 days then 200 mg orally twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tenofovir-lamivudine-efavirenz
Description: 96 weeks of tenofovir disoproxil fumarate 300 mg orally daily, lamivudine 300 mg orally daily, efavirenz 600 mg orally daily
Study: NCT04975282

Intervention type: DEVICE
Intervention: Bottle feeding
Description: Bottle was used as an alternative oral feeding method for preterm infants.

Intervention type: DEVICE
Intervention: Cup feeding
Description: Cup was used as an alternative oral feeding method for preterm infants.
Study: NCT00085852

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BLVR
Description: 10 mL Hydrogel
Study: NCT02961816

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell Infusion
Description: Stem cells administered by vein on Day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: G-CSF administered as an injection just under the skin, per standard of care ,1 time each day starting on Day +5 until blood cell levels return to normal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: G-CSF administered as an injection just under the skin, per standard of care ,1 time each day starting on Day +5 until blood cell levels return to normal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: G-CSF administered as an injection just under the skin, per standard of care ,1 time each day starting on Day +5 until blood cell levels return to normal.
Study: NCT02390752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TURALIO(R)
Description: take oral drug daily for a 28 day cycle
Study: NCT04856579

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Varicocelectomy
Description: Subinguinal varicocelectomy under general anesthesia and complete aseptic condition
Study: NCT02458365

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teen Choices: A Program for Healthy Nonviolent Relationships
Description: A 3-session online, multimedia TTM-based intervention for teen dating violence prevention. For most students, the intervention seeks to reduce risk for dating violence by facilitating progress through the stages of change for using healthy relationship skills; daters are encouraged to use those skills in their dating relationships, and non-daters in their peer relationships, as relationships with peers serve as the foundation for experiences in romantic relationships. For victims of dating violence experiencing fear, the intervention does not focus on healthy relationship skills; instead, it seeks to facilitate progress through the stages of change for keeping oneself safe in relationships.
Study: NCT03266588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimegepant
Description: 75 mg oral tablet
Study: NCT04198129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment (Unasyn or Cleocin)
Description: Trial groups will receive a single post-operative dose administration of Unasyn 3g or Clindamycin 600mg (for penicillin allergies)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment (Augmentin or Cleocin)
Description: the patients in the trial group will be switched to oral Augmentin 875mg twice a day for 7 days, or oral Clindamycin 150mg to 300mg four times a day for 7 days (for penicillin allergies).
Study: NCT03703492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (18F)FES
Description: 18F-FES is an investigational new drug which will be used for this study. For complete information, please refer to the Investigator's Brochure: \[18F\]Fluoroestradiol: An investigational positron emission tomography (PET) radiopharmaceutical for injection, intended for use as an in vivo diagnostic for imaging estrogen receptors in tumors

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine
Description: Gadolinium-based intravenous contrast agent used for the MRI portion of this study
Study: NCT03809871

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cardiometabolic biomarkers
Description: This is for measures of cholesterol (HDL, LDL and total cholesterol), blood glucose and HbA1c, vitamin D, vitamin B12 and iron levels.
Study: NCT00796497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ondansetron
Description: ondansetron hydrochloride (oral solution) dosage of 0.25 mg twice a day for 6 weeks followed by 0,5 mg twice a day for 6 weeks for a total observation period of 12 weeks.
Study: NCT03288480

Intervention type: DRUG
Group type: OTHER
Intervention: PT-112
Description: This is a single arm study
Study: NCT04547504

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg once every 3 weeks for a maximum of 35 cycles or until disease progression, death, unacceptable toxicity, or the Investigator's or the patient's decision to stop.
Study: NCT02458365

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health In Motion
Description: A 3-session online, multimedia, TTM-based intervention which targets physical activity, screen time, and healthy eating for obesity prevention. Health In Motion sessions were administered following the baseline, 6-month, and 12-month assessments to increase the benefits of study participation for Comparison schools and students.
Study: NCT00888030

Intervention type: OTHER
Intervention: there are no interventions currently listed for this study

Intervention type: OTHER
Intervention: there are no interventions currently listed for this study

Intervention type: OTHER
Intervention: there are no interventions currently listed for this study

Intervention type: OTHER
Intervention: there are no interventions currently listed for this study
Study: NCT04547504

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab and Chemotherapy drugs
Description: An induction therapy followed by a maintenance therapy.~4 induction cycles every 3 weeks associating, on the first day of each cycle:~* Cisplatin 75mg/m² or carboplatin AUC 5mg/mL/min, pemetrexed 500mg/m² and pembrolizumab 200mg for non squamous NSCLC.~* Carboplatin AUC 6mg/mL/min, paclitaxel 200mg/m² and pembrolizumab 200mg for squamous NSCLC.~After the 4 induction cycles, a maintenance therapy will be possible for patients who are responding or stable:~* Non squamous NSCLC: pembrolizumab and pemetrexed combination or either drug as monotherapy.~* Squamous NSCLC: pembrolizumab monotherapy.~For pembrolizumab: treatment may be continued for a maximum of 35 cycles or until disease progression, death, unacceptable toxicity, or following the Investigator's or the patient's decision to stop.~For pemetrexed, treatment may be continued until disease progression, death, unacceptable toxicity, or following the Investigator's or the patient's decision to stop.
Study: NCT01446822

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bipolar transurethral resection of the urinary bladder (PlasmaKinetic, Gyrus, Fresenius)
Description: Lateral wall urinary bladder tumors are resected transurethrally without obturator nerve block or relaxation under general anesthesia. If resection not possible because of adductor muscle contraction, patients undergo relaxation.
Study: NCT03241407

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo toothpaste
Description: During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to Placebo group will be submitted to a chemical plaque control (three times per day) using a placebo toothpaste.
Study: NCT04198129

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Control group will not receive any postoperative antibiotics other than what is accepted as preoperative prophylactic antibiotics as per current standards of care
Study: NCT00122018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Study: NCT03241407

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: triclosan/copolymer/fluoride toothpaste
Description: During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to triclosan/copolymer/fluoride group will be submitted to a chemical plaque control (three times per day) using a triclosan/copolymer/fluoride toothpaste.
Study: NCT01825876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Oral administration
Study: NCT02642107

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Elective neck irradiation
Description: Whole neck irradiation is given in the involved neck. Elective neck irradiation of Level II,III and Va lymph node area is given in the uninvolved neck, and Level IV and Vb lymph node area were not irradiated in the uninvolved neck.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole neck irradiation
Description: Whole neck irradiation is given regardless of the involved or uninvolved neck.
Study: NCT05680311

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: measurement of serum autotaxin serum level
Description: autotaxin expression

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: measurement of serum autotaxin serum level
Description: autotaxin expression
Study: NCT02104401

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: tDCS will be applied with a Soterix CT tDCS Device with a HD-tDCS 4x1 Multi-Channel Stimulation Interface. During stimulation, a low level of constant DC electrical current (1-2 mA) will be applied via the electrodes. Current will be ramped up over 10-60 seconds, and typically causes very mild tingling and itching sensations. The current will be applied for no more than 20 minutes per session, at which time the current is ramped down over 10-60 seconds. Subjects will be seated in a chair throughout tDCS administration. Subjects will receive tDCS 5 days/week for 4 weeks.
Study: NCT03608410

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weekly Internet based PRO questionnaires
Description: If core symptoms worsen and exceeds a predefined threshold, a PRO-notification is sent to the hospital.
Study: NCT04089137

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Change (+Change)
Description: This is an integrated social norms-based personalized feedback intervention for college students targeting alcohol misuse and sexual assault. This intervention targets alcohol use, sexual assault victimization risk, sexual assault perpetration, and bystander intervention and is tailored by gender and sexual orientation.
Study: NCT02400827

Intervention type: OTHER
Intervention: malignant cells
Study: NCT03302299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid 300 Mg ORAL TABLET
Description: The study intervention will include a single arm given (1) 6H: 300 mg INH daily by mouth for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridoxine 25 Mg Oral Tablet
Description: All participants will also receive 25 mg pyridoxine (vitamin B-6) daily by mouth for 6 months for the treatment duration to reduce the risk of INH-induced peripheral neuropathy.
Study: NCT02209454

Intervention type: DRUG
Group type: OTHER
Intervention: Enantyum® oral solution
Description: One dose of 25 mg DKP oral solution

Intervention type: DRUG
Group type: OTHER
Intervention: Keral® tablet
Description: One dose of 25 mg DKP tablet
Study: NCT00122018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenoldopam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenoldopam
Study: NCT01345890

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: electrical stimulation
Description: sub motor threshold stimulation of mylohyoid muscles
Study: NCT04052074

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: We are aiming to use music therapy, with pre-recorded favoured music, as a complementary treatment in oncological patients in palliative care, as well as on the carer. It will be performed using mp3 players or mobile phones.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: We are aiming to use music therapy, with pre-recorded favoured music, as a complementary treatment in oncological patients in palliative care, as well as on the carer. It will be performed using mp3 players or mobile phones.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: simulation with therapeutic education
Description: Basic therapeutic education repetition performed to all caregivers and oncological patients in palliative care, through earphones

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: simulation with therapeutic education
Description: Basic therapeutic education repetition performed to all caregivers and oncological patients in palliative care, through earphones
Study: NCT01386619

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD3-depleted/CD56+ selected natural killer cells collected from apheresis products
Description: NK DLI products containing \>1 10e7 NK cells/kg bodyweight (BW) and \< 1 x 10e5 T-cells/kg BW are administered at days +4 (Frankfurt only), and on days +40 and +100 (both centers)
Study: NCT04181554

Intervention type: OTHER
Intervention: Measurement of postural stability
Description: The postural stability will assess by using Biodex balance system.
Study: NCT02815930

Intervention type: OTHER
Intervention: HCU Status
Description: Total healthcare expenditures in the top 5% of Ontarians
Study: NCT01797952

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus CD 2
Description: 2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactobacillus CD 2
Description: 2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The placebo is a mix of sugars and salts used as excipients in the active formulation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is a mix of sugars and salts used as excipients in the active formulation